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Vulnerable Plaque
…Plaque vulnerability 
was defined as the 
susceptibility of a 
plaque to rupture, thus 
causing a clinical 
cardiovascular event.
Plaque vulnerability 
as defined as the 
susceptibility of a 
plaque to rupture, thus 
causing a clinical 
cardiovascular event.
Muller JE et al, Circulation 1989
Plaque rupture vs plaque erosion
75-80% 20-25%
Atherothrombosis
A generalized progressive disease of large- and 
mid-size arteries that affects multiple vascular beds, 
including cerebral, coronary, and peripheral arteries 
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Inflammation and Atherosclerosis
Inflammation in the vessel wall is now
considered to play an essential role in the 
initiation, progression and final steps of 
atherosclerosis, namely plaque destabilization
and eventually plaque rupture.
Infla ation in the vessel all is no
considered to play an essential role in the 
initiation, progression and final steps of 
atherosclerosis, na ely plaque destabilization
and eventually plaque rupture.
Atherothrombosis: 
onset, evolution and rupture
3Endothelial Dysfunction in Atherogenesis The normal endothelium does not in 
general support binding of white blood cells
Vascular endothelium modification
in atherosclerosis
Plaque formation
1 — Fatty streak 
4Plaque formation
2 — Fibrous cap 
Plaque formation
3 — Lipid core 
Vulnerable plaque
Key role of the macrophage in the degradation of the 
fibrous cap
Degradation of the fibrous cap
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5Thrombus formation
Tissue Factor expression within the plaque
? Tissue Factor (TF) is one of the 
major determinants of the 
activation of coagulation cascade 
at site of atherosclerotic plaque 
rupture.
? Several data indicate a positive 
correlation between 
atherosclerotic plaque 
thrombogenicity and Tissue 
Factor expression within the 
plaque. V. Toschi et al, Circulation 1997
Tissue Factor in Atherosclerosis
Atherothrombosis: 
a Immunoinflammatory, Fibroproliferative and 
Progressive Process
.
Most Myocardial Infarctions Are Caused
by Low-Grade Stenoses
Pooled data from 4 studies: Ambrose et al, 1988; Little et al, 1988; Nobuyoshi et al, 1991; and Giroud et al, 1992.
(Adapted from Falk et al.)
6Vulnerable Plaque
high-risk plaque is described as
thin-cap fibroatheroma (TCFA)
- lipid-rich atheromatous core
- thin fibrous cap (<65µm) with
macrophage and lymphocyte
infiltration (inflammation)
- decreased smooth muscle cell
content
- extensive positive remodeling of 
the arterial wall.
high-risk plaque is described as
thin-cap fibroathero a ( F )TC A
- lipid-rich athero atous core
- thin fibrous cap (<65µ ) with
acrophage and ly phocyte
infiltration (infla ation)
- decreased s ooth uscle cell
content
- extensive positive re odeling of 
the arterial wall.
Consensus of the Fist International Vulnerable Plaque Meeting held in Santorini in 2003.
Schaar JA et al, Eur Heart J 2004
…The primary purpose of this natural-history study was to provide
prospective in vivo confirmation of the hypothesis that acute 
coronary syndromes arise from atheromas with certain
histopathological characteristics, and that these characteristics are 
not necessarily dependent on the degree of angiographic stenosis at 
that site.
Despite continuous improvements in the catheter-based treatment of 
coronary artery disease (CAD), our field continues to struggle with
the concept that percutaneous intervention may not prevent
myocardial infarction or death in the stable patient. The main
reason behind this controversial but rather accepted statement is
that life-threatening coronary events arise most frequently from
lesions that escape proper diagnosis and treatment. As a result, our
efforts in clinical practice are almost totally consumed by the 
treatment of lesions that have limited impact on the natural history
of atherothrombosis and CAD. Thus, it is imperative to reflect on 
this paradox, and do something about it….
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that life-threatening coronary events arise ost frequently fro
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efforts in clinical practice are al ost totally consu ed by the 
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Moreno PR, Cir Cardiovasc Interv 2009
7Thrombus formation
Platelet adhesion and activation
…Platelets are multifunctional cells that use
elaborate molecular pathways to regulate a 
variety of thrombotic and inflammatory
responses
Platelets are ultifunctional cells that use
elaborate olecular pathways to regulate a 
variety of thro botic and infla atory
responses
New concepts in Atherothrombosis…
Factors released by activated human platelets
Coagulation Factors
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Chemokines
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Platelet contribution to vessel inflammation
leading to atherogenesis and eventually to
plaque rupture and thrombosis
Platelets provide the inflammatory basis for plaque formation before
physically occluding the vessel by thrombosis upon plaque rupture.
Gawaz M J Clin Invest 2005, 115:3378
8Size comparison of atherosclerotic lesions of LDLR-deficient mice with and without vWf Distribution of atheroisclerotic lesions in the aorta of LDLR-/- vWf+/+
and LDLR-/-vWf-/- mice
…our results indicate that circulating activated platelets and platelet-
leukocyte/monocyte aggregates promote formation of atherosclerotic lesions.
.
9The platelet transcriptome
Gnatenko DV  et al. Blood 2003;101: 2285–93.
Affymetrix HG-U95Av2 probe set (about 12.600 genes) identified the expression of 2147 
(range, 13%-17%) platelet-expressed transcripts, less than half the number (30%-50%) 
expected for nucleated cells. 
Of these, approximately 22% collectively are involved in metabolism and 
receptor/signaling, with a clear overrepresentation of genes with unassigned
function (32%).
Activated platelets mediate inflammatory signaling
by regulated interleukin 1β synthesis.
Lindemann S, et al. J Cell Biol 2001;154(3):485-90
IL-1β mRNA is translated into protein by
activated platelets during fibrin clot formation.
Figure 2. IL-1 is synthesized by platelets in fibrin clots.
(B) Total IL-1 (mean±SEM,n=6) synthesized by resting platelets (Co) 
or platelets activated with thrombin (IIa) (8 h) in the presence or 
absence of puromycin (Puro;100 μM) was determined by ELISA. (C) 
Platelets were pretreatedwith puromycin or DMSO, activated with 
thrombin, and incubated in the presence of [35S]methionine for 8 h. 
The cells were then lysed and the proteins were immunoprecipitated
with an antibody that preferentially recognizes pro–IL-1β. A single 
labeled protein with amolecular mass corresponding to pro–IL-1_was 
identified (arrow).
De Novo Synthesis of Cyclooxygenase-1 Counteracts the 
Suppression of Platelet Thromboxane Biosynthesis by Aspirin
V. Evangelista et al.
Circ Res. 2006; 593-595
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V. Evangelista et al.
Circ Res. 2006; 593-595
Activities of Platelets at the vascular interface
Platelets are multifunctional cells that use elaborate 
molecular pathways to regulate a variety of 
thrombotic and inflammatory responses
Platelets are multifunctional cells that use elaborate 
molecular pathways to regulate a variety of 
thrombotic and inflammatory responses
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Platelets in atherothrombosis
The contribution of platelets in atherothrombosis is no more 
linked only to the last step of the process (thrombus formation
upon plaque rupture).
Platelets play key roles since the early stage of the disease, 
when they contribute to endothelial and monocyte activation, 
leading to plaque progression.
The contribution of platelets in atherothro bosis is no ore 
linked only to the last step of the process (thro bus for ation
upon plaque rupture).
Platelets play key roles since the early stage of the disease, 
when they contribute to endothelial and onocyte activation, 
leading to plaque progression.
.
